Fresh analysis suggests that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Findings released in a prominent health publication shows that while overweight individuals can lose about a fifth of their body weight while using the jabs, the mass returns at an average rate of nearly a kilo each month after stopping.
"Users purchasing these treatments must be cognizant of the potential of quick rebound weight gain when the treatment is stopped," warns researcher Dr. Susan Jebb.
This pace of regain implies a return to pre-treatment mass within about a year and a half.
Analyzing Approaches
The study, which looked at dozens of trials involving thousands of patients, contrasted the outcomes of the injectable medications with older methods.
Scientists emphasize that individuals who shed pounds through dieting typically have a slower creep back—around 0.1 kg a month—post-intervention.
Explaining the Rapid Regain
Doctors believe the way of the jabs accounts for the heightened rebound.
The injections copy a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of the hormone levels several times higher than normal may cause the system to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' leads to hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Issue?
The NHS suggest the jabs for people with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians contend that, due to the likelihood of weight regain, the therapy might need to be life-long.
This perspective is reinforced by drug manufacturers, who note that the results "highlight the persistent nature of excess weight," akin to managing conditions like diabetes.
User Experiences
Individuals who have discontinued the medication report a sudden resurgence of cravings.
"I experienced a switch flipping and you're instantly starving," said one woman.
This difficulty is worsened if individuals have not adopted permanent dietary or behavioural changes during therapy.
Growing Interest
Survey data indicate that millions of people in the UK have tried these injections in the past year, with demand being substantial.
- Use is higher among females compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, clinicians caution that while these medications are powerful agents for shedding pounds, they are not a permanent cure and lasting health benefits relies on integrated behavioural support.
